Artelo Biosciences
ARTL
2 hedge funds and large institutions have $15K invested in Artelo Biosciences in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
61% less capital invested
Capital invested by funds: $38K → $15K (-$23K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.34K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Goldman Sachs
New York
| $14K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $1K | +$1.34K | +3 | New |
|
ARTL Hedge Fund Activity: Q1 2020 in Review
2 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2020, worth a combined $15K — down 61% from $38K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ARTL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.34K.
- 2 institutional investors held Artelo Biosciences (ARTL) as of Q1 2020, up from 1 in Q4 2019.
- Funds reported $15K of Artelo Biosciences stock for Q1 2020, down 61% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q1 2020 and 0 closed out, a net change of +1 holder.
- The largest Artelo Biosciences buyer in Q1 2020 was UBS Group, an estimated $1.34K added.
Based on aggregated 13F filings for Q1 2020.